Literature DB >> 16440035

[Whooping cough--an increasing problem in Norway].

Susanne Gjeruldsen Dudman1, Marius Trøseid, Tom Øystein Jonassen, Martin Steinbakk.   

Abstract

BACKGROUND: The incidence of whooping cough has increased in recent years in Norway, especially amongst older children and adults; in 2004 it was 168/100,000.
MATERIAL AND METHODS: This article is based on our own experience and a review of available literature, identified on Medline with the search word "pertussis". RESULTS AND
INTERPRETATION: Whooping cough, a disease caused by the bacterium Bordetella pertussis, is transmitted via respiratory droplets. Sources of infection for infants are often their parents and siblings. Older children and adolescents contract whooping cough mostly in school, whereas adults usually get the disease from children or colleagues. The typical symptoms are bouts of violent coughing with the classic whoop and post-tussive vomiting. A milder clinical picture can be seen in vaccinated persons, reinfected patients, and in persons above the age of 15. Infants are most at risk of developing serious disease and have the highest numbers of hospitalizations, complications and mortality. But complications are also seen in adolescents and adults, including urinary incontinence, rib fractures and pneumonia. The diagnosis is made by culture or PCR in nasopharyngeal secretions, as well as by detection of antibodies to B. pertussis in serum. If treatment is indicated, macrolides are the drugs of choice; these shorten the duration of symptoms and the period of contagiousness if given in the early stages of the disease. To help combat whooping cough in Norway, from 2006 an extra vaccine booster dose will be given to children at the age of seven.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16440035

Source DB:  PubMed          Journal:  Tidsskr Nor Laegeforen        ISSN: 0029-2001


  6 in total

1.  Strain variation and antigenic divergence among Bordetella pertussis circulating strains isolated from patients in Iran.

Authors:  Fatemah Sadeghpour Heravi; Vajihe Sadat Nikbin; Masomeh Nakhost Lotfi; Pouran Badiri; Nazanin Jannesar Ahmadi; Seyed Mohsen Zahraei; Fereshteh Shahcheraghi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-09       Impact factor: 3.267

2.  Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine.

Authors:  Jennie S Lavine; Ottar N Bjørnstad; Birgitte Freiesleben de Blasio; Jann Storsaeter
Journal:  Vaccine       Date:  2011-11-26       Impact factor: 3.641

Review 3.  Resolving pertussis immunity and vaccine effectiveness using incidence time series.

Authors:  Jennie S Lavine; Pejman Rohani
Journal:  Expert Rev Vaccines       Date:  2012-11       Impact factor: 5.217

4.  Respiratory tract infections during the 2011 Mycoplasma pneumoniae epidemic.

Authors:  N Reinton; L Manley; T Tjade; A Moghaddam
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-25       Impact factor: 3.267

5.  Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012.

Authors:  M van Gent; C J Heuvelman; H G van der Heide; H O Hallander; A Advani; N Guiso; C H Wirsing von Kőnig; D F Vestrheim; T Dalby; N K Fry; D Pierard; L Detemmerman; J Zavadilova; K Fabianova; C Logan; A Habington; M Byrne; A Lutyńska; E Mosiej; C Pelaz; K Gröndahl-Yli-Hannuksela; A M Barkoff; J Mertsola; A Economopoulou; Q He; F R Mooi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-20       Impact factor: 3.267

Review 6.  Pertussis. A reemerging and an underreported infectious disease.

Authors:  Muhammad A Syed; Noureen F Bana
Journal:  Saudi Med J       Date:  2014-10       Impact factor: 1.484

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.